Drugmaker Bristol Myers Squibb has been a standout among its big pharma peers over the past six months, scoring a share-price ...
Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the ...
The pharmaceutical company plans to cut $2 billion in annual expenses by the end of 2027 through “operational efficiencies across multiple areas of the business,” its CFO told analysts on a conference ...
The drugmaker Bristol Myers Squibb has been a standout among its big pharma peers over the past six months, scoring a ...
Qualcomm trades lower after earnings, Eli Lilly stock rises on upbeat guidance, Skyworks says its share of the business to ...
Bristol Myers Squibb on Thursday posted better-than-expected fourth quarter earnings, but said its 2025 revenue would fall ...